NCT Number: NCT00236522
A Comparison of the Safety and Efficacy of Two Different Regimens of Levofloxacin in the Treatment of Acute Bacterial Sinusitis(Sinus Infection) in Adults.
The purpose of this study is to evaluate the effectiveness and safety of two antibiotic regimens in the treatment of acute bacterial sinusitis (sinus infection) in non-hospitalized adult patients. A 5-day course of 750 milligrams of levofloxacin given by mouth once daily will be compared to a 10-day course of 500 milligrams of levofloxacin given by mouth once daily.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
About this study
When treating sinus infections (sinusitis) caused by bacteria, the traditional duration of therapy is between 10 and 14 days. In this randomized, double-blind study, 5 days of 750 milligrams of levofloxacin given once daily will be compared to 10 days of 500 milligrams of levofloxacin in the treatment of non-hospitalized adult patients who have acute bacterial sinusitis. To prevent the study doctor, study staff and patients from knowing which study drug they are taking, all study drug will manufactured to look the same and patients on the 5-day regimen will be given placebo for the last 5 days of their participation in the study. Patients will have a sinus specimen collected at the first visit. Safety evaluations will be conducted. The objective of the study is to demonstrate that, in the treatment of acute bacterial sinus infections, a 5-day course of 750 milligrams of levofloxacin given once daily is at least as effective as a 10-day course of 500 milligrams of levofloxacin given once daily and is well tolerated.
Patients will take by mouth 750 milligrams levofloxacin capsules once daily for 5 days followed by placebo capsules once daily for 5 days, or 500 milligrams levofloxacin capsules once daily for 10 days.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Diagnosis of acute bacterial sinusitis, defined by clinical signs and symptoms lasting for less than 28 days and the presence of visible nasal infection, and confirmed by computed tomography (CT) or standard sinus x-rays
- Two or fewer episodes of bacterial sinusitis within the preceding 12 months
- Willing to undergo maxillary sinus puncture or endoscopy
Exclusion criteria
- Chronic sinusitis
- Use of systemic antibiotics within the past 72 hours
- Presence or history of serious complications of sinusitis
- Surgery for treating sinusitis
- Required daily use of more than 20 milligrams of prednisone (oral steroid)
- Cystic fibrosis
Treatment and study plan
Primary outcomes
-
Clinical success (resolution of patient signs and symptoms) at the post-therapy visit.
Secondary outcomes
-
Microbiologic response at the post-therapy visit and safety evaluations.
Sponsors and collaborators
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Collaborators
- PriCara, Unit of Ortho-McNeil, Inc.
Registry information
Official study title
A Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Levofloxacin 750 mg Once Daily for 5 Days Versus Levofloxacin 500 mg Once Daily for 10 Days in the Treatment of Acute Bacterial Sinusitis in Adults.
Important dates
- Study start
- 2002
- Study completion
- 2004
- First posted
- Oct 12, 2005
- Registry last updated
- Jun 10, 2011
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Dupilumab in CRSsNP
NCT04678856
Chronic Rhinosinusitis Without Nasal Polyps, Chronic Sinusitis
Roseville, California, United States
View Trial DetailsClinical Outcomes and Patient Satisfaction With Velnez Versus Nasopore in Nasal Surgery
NCT07560254
Chronic Rhino-sinusitis, Infections
Sungai Buloh, Selangor, Malaysia
View Trial DetailsEndoscopic Assessment of Schneiderian Membrane Perforation During Osseodensification-mediated Transcrestal Sinus Floor Elevation With Graftless Immediate Implant Placement in Subsinus Bone Height of 4-6 mm: A Pilot Study.
NCT07542275
Infections, Mouth Diseases
Beirut, Lebanon
View Trial DetailsBest Practice in the Management of Concha Bullosa in FESS Operation
NCT06687629
Concha Bullosa, Infections
Helsinki, Uusimaa, Finland
View Trial Details